Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Rodney Lindsay

Family Medicine Carrollton, TX Medical Doctor

NPI 1568458867 CMS profile 343617

4343 N Josey Ln, Carrollton, TX 75010

Open in the dashboard

General payments

$224,655

519 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Rodney Lindsay of Carrollton, TX is reported in the CMS Open Payments database as having received $224,655 across 519 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 99th percentile of Family Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $28,105 38
2024 General $44,155 47
2023 General $33,248 88
2022 General $28,376 82
2021 General $30,389 87
2020 General $8,492 29
2019 General $51,889 148

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Rodney Lindsay
  • Family Medicine median
  • Middle half of Family Medicine
  • National median

In program year 2025, general payments to Rodney Lindsay were reported at $28,105. Among 56,786 Family Medicine profiles paid that year, the median was $155 and the middle half received between $45 and $549.

Show as a table
Year Rodney Lindsay Family Medicine median Middle half National median
2019 $51,889 $150 $41–$543 $163
2020 $8,492 $120 $32–$415 $114
2021 $30,389 $137 $35–$551 $132
2022 $28,376 $137 $37–$512 $149
2023 $33,248 $149 $42–$545 $160
2024 $44,155 $156 $44–$560 $164
2025 $28,105 $155 $45–$549 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Smith+Nephew, Inc. $213,821 461 payments
  2. Misonix Inc $6,792 15 payments
  3. Osiris Therapeutics Inc. $2,247 7 payments
  4. ETS Wound Care LLC $387 7 payments
  5. Kerecis Limited $320 3 payments
  6. Acera Surgical, Inc. $246 1 payment
  7. Reprise Biomedical, Inc. $189 2 payments
  8. Amniox Medical, Inc. $125 1 payment
  9. Keswick Pharmaceuticals LLC $104 1 payment
  10. LifeNet Health $86 5 payments
  11. Other $340 16 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $107,950 62 payments
  2. Consulting Fee $59,287 27 payments
  3. Travel and Lodging $42,607 206 payments
  4. Food and Beverage $11,585 220 payments
  5. Compensation for serving as faculty or as a speaker for a non-accredited and noncertified continuing education program $3,226 3 payments
  6. Education $1 1 payment
Products named General payments · program years 2019–2025
  1. COLLAGENASE SANTYL Pharma Products $82,938 139 payments
  2. GRAFIX $46,236 52 payments
  3. Santyl $36,160 107 payments
  4. GRAFIX PL $33,011 66 payments
  5. ALLEVYN LIFE L 15.4X15.4 CTN10 $29,750 14 payments
  6. PICO $29,151 19 payments
  7. REGRANEX $27,588 77 payments
  8. GRAFIX XC $23,300 29 payments
  9. COLLAGENASE SANTYL Pharma Product $23,276 54 payments
  10. Oasis $21,117 51 payments
  11. Other $141,666 344 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 12 drugs

Part D claims

315

Median for Family Practice: 1,826

Drug cost

$38,962

Median for Family Practice: $120,094

Branded share of claims

25.7%

Median for Family Practice: 18.9%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Santyl Collagenase Clostridium Hist. Brand 31 $31,729
Betamethasone Valerate Generic 91 $2,876
Gentamicin Sulfate Generic 20 $1,024
Doxycycline Hyclate Generic 29 $701
Lidocaine Generic 17 $599
Cefdinir Generic 18 $499
Nitro-Bid Nitroglycerin Brand 11 $403
Clotrimazole-Betamethasone Clotrimazole/Betamethasone Dip Brand 19 $349
Clindamycin Hcl Generic 26 $273
Hydrocodone-Acetaminophen Hydrocodone/Acetaminophen Brand 20 $254

The 10 drugs with the highest cost, of 12 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 105,120 Part D prescribers listed as Family Practice; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 19 billing codes

Paid by Medicare

$72,734

Medicare's payments for the services billed

Medicare patients

104

Average age 76

Services billed

1,398

57 women, 47 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 67%
Diabetes 52%
Chronic kidney disease 50%
Ischemic heart disease 43%
Depression 42%
COPD 35%
Atrial fibrillation 33%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

519 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Family Medicine in Texas

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record